To consolidate our basic scientific and technological appreciation of human regulatory macrophages (M reg) as a cell-based medicinal product for use as an adjunct immunosuppressive therapy in organ transplantation.
INTRODUCTION
Although conventional maintenance immunosuppression is superbly effective in preventing acute transplant rejection, it has many unintended consequences, not least renal toxicity, metabolic disturbances, cardiovascular disease and increased susceptibility to infection and malignancy [1] . For this reason, and because gains in long-term transplant survival have not matched the considerable short-term improvements, strategies to induce allograft tolerance remain an active topic of research [2] . Regrettably, attempts to translate experimental tolerance-promoting protocols into clinical practice have, so far, not resulted in a well tolerated, consistent and clinically acceptable treatment [3] . On the other hand, recent advances in lymphodepletive induction strategies [4, 5] , combined bone marrow and solid organ transplantation [6] , and cell-based immunomodulatory therapy [7 && ,8,9] encourage the belief that clinical tolerance induction remains an achievable goal [10] .
Transferring immunoregulatory cells from tolerant animals into a naïve recipient as a means of achieving allograft acceptance is a long-established technique in Transplant Immunology, but its application in clinical transplantation is only now receiving serious attention. Several alternative cell types are currently at the point of preclinical development that might allow them to be properly investigated as adjunct immunosuppressive therapies in early-stage clinical trials [11] [12] [13] . One particularly promising candidate cell type, the regulatory macrophage, has been a focus of research in our laboratory over several years [7 && ,14] . This review aims to provide a coherent description of the human regulatory macrophage (M reg) as a medicinal product and to give the reader an impression of its current state of clinical development.
The use of manipulated cells as medicinal agents is very much in its infancy, but the field is expanding rapidly. Isolating, propagating and modifying cells ex vivo before administering them to a patient allows, in principle, the replacement of specific cellular functions, which opens astonishing new possibilities for gain-of-function treatments of degenerative and immunological diseases. The substantial public and private investment in facilities for producing and administering cell-based therapies reflects a confidence in their eventual clinical applicability [15, 16] . Consequently, clinicians must begin to think about the nature of cell-based therapies, how to adopt such treatments into clinical practice and the logistical challenges they present.
In order to use any therapeutic agent safely and effectively, clinicians must know about its pharmacological properties to predict efficacy and safety in individual patients. Specifically, a clinician must know about the pharmacokinetics (absorption, tissue distribution, metabolism and elimination) and therapeutic dose range of a drug, as well as having an understanding of its mechanism of action and potential adverse effects [17 & ]. Although cell-based medicines are quite different in nature from chemically synthesized drugs, the same general clinical considerations apply, and these are now codified in European Law [18] [19] [20] . Cell-based medicines are perhaps best thought of as cell transplants, rather than as drugs, because living cell preparations are inherently heterogeneous in composition and effect, and rest upon transplantation of cellular functions as a therapeutic basis. Nevertheless, cell products can be made to conform to our usual expectations of a drug in most respects, as laid out in the European Medicines Agency (EMA) Guidelines on human cell-based medicinal products [21 & ].
THE INTERFACE OF SCIENCE AND TECHNOLOGY
It is helpful here to emphasize the distinction between scientific and technological modes of research, a separation which is crucial to an historical understanding of the discovery of M regs [22] . Building from his original observation that allogeneic myeloid cells arising naturally from earlier, uncommitted precursors could induce indefinite allograft acceptance, Fändrich et al. [23] pursued the concept of using macrophages as a cell-based tolerance-promoting therapy. Fändrich's pivotal realization was that his technological objectives did not necessarily depend on a complete scientific appreciation of the role of macrophages in tolerance induction or maintenance. Accordingly, Fändrich geared his research programme towards early proofof-concept studies in patients, leading to the TAIC-I and TAIC-II clinical trials, which we describe below [24] [25] [26] [27] .
Research in our laboratory followed an alternative direction, trying to establish an immunological basis for the effects reported by Fändrich [28, 29] . We took as our starting point the demonstration that intravenous administration of crude preparations of macrophage colony-stimulationg factor (M-CSF) and IFN-g-stimulated macrophages prolonged allograft survival [30] . These impure cell mixtures, which Fändrich called transplant acceptance-inducing cells or TAICs, were shown to contain populations of T-cell-suppressive macrophages that varied greatly in their phenotypes. An understanding of how monocytes gradually transition to macrophages in TAIC cultures led to an explanation of this heterogeneity and, further, to the identification of a steady-state product of this process, which we called the regulatory macrophage. We have now arrived at a rigorous phenotypic description of the M reg and understand how it relates to other invitro-derived and physiologically occurring macrophage populations. Several factors driving M reg development in vitro have been defined and the mechanisms underlying M reg-mediated T-cell suppression are now known [7 && ]. A clear distinction can be drawn between crude TAIC preparations, which are impure mixtures of differently activated macrophages contaminated with other leucocytes, and refined M reg preparations, which comprise a relatively uniform
KEY POINTS
The human regulatory macrophage conforms to our requirements of a cell-based medicinal product.
Preliminary clinical studies show that manufacturing and administering regulatory macrophages to renal transplant recipients is feasible.
The concept of promoting renal allograft acceptance by preoperative treatment of transplant recipients with donor-derived regulatory macrophages is being carried forward within The ONE Study, a multinational clinical trial of cell therapy in kidney transplantation supported by the European Union. population of macrophages. It is noted that M regs constitute only a small proportion of macrophages present in TAIC preparations. The purity, phenotypic homogeneity, stability and consistent T-cellsuppressive activity of M reg preparations make them more suitable than TAICs for use as a cellbased medicine. Processes for manufacturing M regs under good manufacturing practice conditions have been established and two patients have now been treated with these superior cell products [7 && ]. Thus, lessons from our basic scientific studies are feeding back into clinical applications.
HUMAN REGULATORY MACROPHAGE MANUFACTURE AND QUALITY ASSESSMENTS
M regs derive from purified human peripheral blood monocytes isolated by positive selection of CD14expressing cells using magnetic bead selection [14] . Leucocytes used as the starting material in this process are obtained from a single donor by leucapheresis ( Fig. 1 ). The differentiation of monocytes to M regs occurs gradually over a 7-day culture period during which the cells are exposed to M-CSF and human AB serum-containing medium, and a final 24-h pulse of IFN-g. On the 7th day of culture, M regs are harvested and then resuspended in 5% human albumin in normal saline for immediate administration by central venous infusion. A single batch of M regs is administered to one recipient at a single time-point; batches of M regs are not split between multiple recipients or multiple administrations.
In-process controls must be performed at every step in the manufacturing process to ensure that the product conforms to specified criteria regarding composition, yield and microbiological sterility [21 & ]. The composition of an M reg preparation is judged by the identity of its active cellular component, purity and impurities. The identity of an M reg is adequately defined by its morphology and marker phenotype: M regs grow as an adherent monolayer and individual cells adopt a typical morphology; expression of human leukocyte antigen DR (HLA-DR) and CD86 is consistently high in M regs, whereas cell-surface expression of CD14, CD16, CD80, CD163 and CD282 is low or absent [7 && ]. M reg cultures containing cells with abnormal forms, or those in which fewer than 90% of cells exhibit the correct phenotype, should be discarded. M reg preparations with unacceptable levels of cellular contaminants [including T cells, B cells, natural killer (NK) cells, erythrocytes and thrombocytes] should also be rejected. Likewise, in order to limit the risk of sensitizing recipient against donor, it is important that M reg preparations administered to patients do not contain a high proportion of dead cells. Impurities of the final cell product, such as medium components or adventitious microbial agents, may be unintentionally introduced during the cell culture process; the presence of these contaminants must be stringently excluded in benchrelease testing [31] .
When cocultured with polyclonally activated allogeneic T cells in vitro, M regs profoundly suppress proliferation, in part through the action of indoleamine 2,3-dioxygenase (IDO). As IDO has been shown to be indispensable for maintaining maternal tolerance of allogeneic conceptuses in mice and participates in the establishment of allograft tolerance by adoptive transfer of T regs, it is at least plausible that M regs could exert a therapeutically beneficial effect through IDO in renal transplant recipients [32, 33] . Accordingly, the IDO-mediated suppression can be taken as the basis of a potency assay to assess the functional quality of M reg Stem cell transplantation preparations [34] . Human M regs were found to eliminate activated T cells in direct coculture and this activity also forms the basis of an assay of M reg action. A clinically applicable test of human M reg activity in an animal model has not yet been established, although an in-vivo potency assay might eventually provide a more relevant read-out of functional capability than in-vitro testing.
PHARMACOLOGY AND TOXICOLOGY OF HUMAN REGULATORY MACROPHAGES
An experimental proof-of-concept has been made using M regs in several animals models, including heterotopic heart transplantation in murine systems and lung transplantation in miniature swine [35] . However, the value of these homologous animal models must be critically evaluated with regard to their relevance to human M reg therapy. Quite obviously, the strength of any inference drawn about the potential effects of human M regs in humans by studying animal M regs in animal models depends upon the degree of equivalence between animal and human M regs. Functional equivalences between animal and human cell types are very difficult to define, and this situation is especially true of highly specialized subsets of myeloid cells [36] . Therefore, heterologous models of M reg function may ultimately prove to be more relevant and informative test systems. In this regard, we view the development of a reconstitution model of human transplant arteriosclerosis, described recently by Nadig et al. [37 && ], as an extremely important achievement.
M regs administered to experimental animals by intravenous injection are thought to distribute widely throughout lymphoid and nonlymphoid tissues. At the present time, the location of their important biological effects is not known; however, after systemic delivery, the spleen is an obvious potential site of M reg interaction with the recipient immune system. Given their broad distribution, it is a theoretical concern that M regs might suppress protective immune responses to opportunistic pathogens or spontaneously arising tumours, but evidence of such effects was not found in conventional toxicology studies (Fändrich F, personal communication) or early-stage clinical trials (see below).
In general terms, the potential clinical complications of administering M regs to a patient by central venous infusion can be classified as physiological, immunological, infective or neoplastic. Possible physiological complications include embolism of cellular aggregates and biochemical disturbances due to massive release of cellular constituents; however, such complications were not observed in mouse studies using clinically relevant M reg doses. Potential immunological problems arising from allogeneic M reg infusion might include sensitization of the recipient against donor antigen, immediate or delayed transfusion reaction-like reactions, excessive immunosuppression and graftversus-host reactions. These complications have not been observed in patients and were not evident in toxicological studies performed in mice, although it must be conceded that naïve mice might not respond as an immunologically experienced human. Transmission of infection with M reg preparations is an unlikely complication as rigorous microbiological screening of the cell donor and the cell product guards against this eventuality. M regs are thought to be terminally differentiated and nondividing, accordingly their life-span in an allogeneic recipient is unlikely to be indefinite, and so their potential to give rise to malignancies is limited. This contention is supported by studies in immunodeficient mice, which found no evidence of M regs themselves being tumourigenic or promoting spontaneously occuring malignancies.
EARLY CLINICAL TRIALS IN TRANSPLANTATION
Bringing a cell-based immunosuppressive therapy into early-stage clinical trials is a challenging task, not least because short-term transplant outcomes are generally excellent and placing patients at additional risk without clear benefit is not justifiable. The crux of the problem is that immunosuppressive therapy is inherently harmful, so phase I trials in normal, healthy volunteers are not ethical; on the contrary, treating transplant recipients with novel immunosuppressants is not safe unless the agent is also efficacious. Therefore, early-phase trials of immunosuppressive agents in transplantation must, almost inescapably, assess both safety and efficacy in combination. Moreover, the very nature of cell-based therapeutic agents poses various complications for their delivery to patients within a clinical environment unused to working with biological products. Because of these special clinical considerations, alternative approaches to conventional phase I and II studies are justified, including exploratory trial designs which examine both safety and efficacy outcomes without seeking confirmatory outcomes [21 & ]. In 2003, Fändrich initiated the TAIC-I trial to assess the clinical feasibility and tolerability of administering donor-derived TAIC preparations to recipients of renal transplants from deceased donors [24] . The 10 patients in the study received between 0.5 and 7.5 Â 10 6 donor-derived TAICs/kg bodyweight, administered by central venous infusion 5 days post transplant. No acute complications or no later adverse reactions relating to the cell infusion were observed. Thus, TAIC-I demonstrated the clinical feasibility of producing and administering TAICs to transplant patients, and provided no evidence that TAIC administration is unsafe.
The TAIC-II trial commenced in 2005 with the objective of assessing the feasibility, safety and immunological effects of administering donorderived TAIC preparations to renal transplant recipients prior to transplantation [25] . Patients enrolled in TAIC-II were listed to receive living-donor renal transplants. Between 1.7 and 10.4 Â 10 6 donorderived TAICs/kg were administered to each patient 5 days prior to transplantation. The immunosuppressive protocol was as follows: antithymocyte globulin (ATG-Fresenius) was given on days 0, 1 and 2; tacrolimus with trough levels of 5-12 ng/ml and conventional steroid therapy began on day 0; steroids were weaned by week 8; then, tacrolimus treatment was reduced to 5-8 ng/ml by week 20 and to less than 4 ng/ml after week 24. Of the five patients analysed in TAIC-II, treatment of four patients was successfully minimized to low-dose tacrolimus monotherapy. No rejection occured in two of five patients. One patient underwent a rejection episode at 36 weeks after reduction of tacrolimus treatment to less than 2 ng/ml for 6 weeks. The two remaining patients experienced acute rejection episodes only after complete cessation of immunosuppression for 2 and 34 weeks. Patients treated with TAICs exhibited attenuated donor-specific responses, but not third-party responses, in mixed lymphocyte reactions. Thus, TAIC-II demonstrated the feasibility of preoperative TAIC treatment and added to body of observations that TAIC treatment is well tolerated. That TAIC-treated patients were able to tolerate moderately aggressive minimization of tacrolimus to subtherapeutic levels, viewed in the context of reduced antidonor responses in vitro, hints at TAIC-treated patients having achieved a degree of immunological unresponsiveness against their donor.
HUMAN REGULATORY MACROPHAGES ARE A HIGHLY REFINED CELL PRODUCT WITH THE ESSENTIAL DRUG-LIKE QUALITIES REQUIRED FOR CLINICAL APPLICATION
As already discussed, the crude TAIC preparations used in the TAIC-I and TAIC-II trials do not conform to our requirements of a cell-based medicinal product in a number of important respects. Identification of the M reg as an active component of TAIC preparations and an appreciation of the processes underlying M reg development in culture led to development of improved manufacturing techniques, resulting in cell products with more consistent yields and less phenotypic heterogeneity. These purer, more uniform M reg preparations have now been applied to two living-donor renal transplant patients and the 3- Patient C.A., a 47-year-old male received a fully mismatched kidney from an unrelated 40-year-old living donor. Seven days prior to transplantation, 7.1 Â 10 6 donor-derived M regs/kg were administered to C.A. by slow central venous infusion. He was subsequently treated with a combination of azathioprine, steroids and tacrolimus. Azathioprine was withdrawn by week 8 and steroids stopped by week 10. Protocol biopsies at 8, 24 and 52 weeks showed no signs of rejection. At 3 years, C.A. had stable renal function and is now being maintained with sustained-release tacrolimus 5 mg omne in die with a trough tacrolimus level of 2.7 ng/ml.
To assess the distribution and rate of M reg elimination after administration to a patient, a fraction of the cells administered to M.M. were labelled with 111 Indium-oxine, allowing them to be tracked in single-photon emission computed tomography imaging studies (Fig. 2) . M regs given by central venous infusion were found to pass through the lungs and via the blood to accumulate in the liver, spleen and haematopoietically active bone marrow within 30 h. The relative absence of tracer in the urinary tract strongly suggests that the majority of infused M regs remained alive for the duration of the study [38, 39] . The longer-term fate of M regs in allogeneic recipients is still unknown. To formally assess the risk of cell emboli lodging in the lung vasculature, patient C.A. was intensively investigated for signs of disturbed pulmonary blood flow after M reg infusion: No clinical, biochemical or ECG signs of pulmonary embolism were detected and ventilation-perfusion scintigraphy revealed no evidence of localized or generalized defects in perfusion.
A groundbreaking study conducted by the IOT-RISET (Indices of Tolerance -Reprogramming the Immune System for the Establishment of Tolerance) network defined a pattern of peripheral blood gene expression associated with a drug-free, tolerant state in renal transplant recipients [40 && ]. As a measure of the pharmacodynamic effect of M regs, expression of the 10 most discriminatory gene markers of tolerance identified by the IOT-RISET group was assessed in serial blood samples taken from patients M.M. and C.A. Over the first year post transplant, the pattern of expression of these markers gradually converged upon the IOT-RISET signature. The proper interpretation of these findings is yet unclear because the IOT-RISET signature has not been prospectively validated and the impact of immunosuppression on marker gene expression is not fully resolved; however, at least, the data are not inconsistent with the idea that patients M.M. and C.A. might have achieved a degree of immunological regulation against their donors.
CONCLUSION
A view of the human regulatory macrophage as a pharmaceutical agent has been presented; this description will seem somewhat alien to macrophage biologists, but clinicians should begin to appreciate how M regs might perform as a real-world therapeutic. That said, there remains much work to be done in developing M regs as a immune-conditioning treatment because, encouraging as the preliminary data might be, they do not constitute evidence of safety or beneficial effect. The concept of using M reg therapy as a means of establishing renal transplant recipients on low-dose tacrolimus monotherapy is now being carried forward within The ONE Study, a project supported by the European Union 7th Framework Programme (www.onestudy.org). This exciting project aims to directly compare the tolerance-promoting potential of T regs, Tr1 cells, tolerogenic dendritic cells and M regs. Thus, after many years of open speculation, The ONE Study will finally answer the question as to whether M reg treatment, or immunoregulatory cell-based therapy in general, has any place in the clinical management of solid organ transplant recipients.
